Bausch + Lomb (NYSE:BLCO), traded on the New York Stock Exchange under the ticker BLCO, is a global eye health company with roots dating back to 1853 in Rochester, New York. Originally founded as an optical shop by John Bausch and Henry Lomb, the company has evolved over more than a century into a leading developer and manufacturer of products designed to preserve and enhance vision. In 2024, Bausch + Lomb completed its separation from its former parent company and began trading as an independent, publicly listed entity focused exclusively on eye health.
The company’s product portfolio spans four primary categories: contact lenses, lens care solutions, ophthalmic pharmaceuticals and surgical products, and advanced surgical instruments. Bausch + Lomb offers a broad range of contact lens modalities, including daily disposables, monthly and multifocal lenses, as well as toric designs for astigmatism. Its lens care division features branded solutions that support comfort and eye health, while its pharmaceutical business develops treatments for glaucoma, dry eye and retinal disorders. The surgical line includes intraocular lenses, microscopes and a suite of devices used in cataract, refractive and vitreoretinal procedures.
With a presence in more than 100 countries, Bausch + Lomb serves eye care professionals, hospitals and consumers across the Americas, Europe, the Middle East, Africa and the Asia-Pacific region. The company maintains a network of manufacturing facilities in North America and Europe, complemented by research centers focused on novel drug delivery systems, next-generation lens materials and digital vision technologies. Distribution is supported by a combination of direct sales forces, strategic partnerships and global supply chain capabilities.
Guided by a seasoned executive leadership team with decades of experience in ophthalmology and medical devices, Bausch + Lomb invests heavily in research and development to drive sustained innovation. The company routinely collaborates with academic institutions, clinicians and research organizations to expand its pipeline and address unmet needs in vision care. As a standalone public company, Bausch + Lomb is committed to leveraging its heritage, deep product expertise and global footprint to help millions of people worldwide see better and live better.
